Engineering precision immunity
Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer and infectious diseases with potent lymph node targeted immunotherapies and vaccines. Elicio’s Amphiphile platform combines expertise in materials science and immunology to develop novel immunotherapies and vaccines, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.
Lymph nodes:
where the immune response is orchestrated
Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, resulting in tumor or pathogen targeted immunity, including potent T cell and humoral responses. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in early 2021.
NEXT-GENERATION IMMUNO-ONCOLOGY PLATFORM
Our programs
Elicio’s core business is the development of therapeutic cancer vaccines. ELI-002, its lead clinical program, is designed to stimulate an immune response against the seven Kirsten rat sarcoma (KRAS) mutations driving 25% of solid tumors. ELI-002 is currently being studied in AMPLIFY-201, a Phase 1 dose escalation study, and AMPLIFY-7P, a Phase 1/2 study.
Latest News
April 5, 2024 ||
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells 84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD8+ T cells The majority of ELI-002-treated patients tested had antigen spreading where induced T cells targeted additional patient-specific... » Read more
March 29, 2024 ||
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024 ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR Annual Meeting 2024 Phase 2 randomized trial in PDAC is underway with enrollment expected to... » Read more
Elicio Corporate Presentation
Koch Institute Symposium: Targeting the Lymph Nodes to Orchestrate Anti-tumor Immunity